Surrogacy in Greece: Medical and Donor Requirements
What is law, and what is a clinic rule?
A Greek fertility clinic may consider a proposed surrogacy cycle medically feasible, yet that does not establish that it is legally admissible. The decision has several separate gates: the intended mother's documented inability to carry a pregnancy; the proposed carrier's health suitability; lawful embryo and donor arrangements; and effective judicial permission before embryo transfer. Clinic protocols can impose further medical conditions but cannot waive a statutory restriction. This guide separates these questions under Greek law, rather than promising eligibility based on a consultation alone.
This analysis addresses clinical and gamete requirements in Greece, not the complete rules on nationality, the applicants' family status, commercial intermediaries, parentage or a child's travel documents. Those issues require independent review. The critical framework is Civil Code article 1458 as changed by Law 5197/2025, assisted-reproduction Law 3305/2005, the 2022 regulator decision and later donor/PGT directions. These sources have different legal force: legislation, published regulatory decisions, official instructions and a clinic's own case-by-case judgment are not equivalent.
Medical necessity and the current legal gateway
The woman applying to become the intended mother must prove that it is medically impossible for her to carry a pregnancy. This is not automatically established by difficulty conceiving, repeated failed IVF cycles, advancing age or a preference to avoid pregnancy. A specialist should identify the condition, explain why gestation cannot be undertaken, and support it with relevant records. The court makes the legal assessment. The 2025 amendment expressly says that inability to carry due to sex does not meet this statutory medical ground.
The same article requires proof that the proposed gestational carrier is medically fit to carry. A normal preliminary consultation or an IVF clinic's willingness to accept her is not itself a judicial finding. Ask the treating team for a written assessment addressing obstetric history, current health, foreseeable pregnancy risk and any investigations necessary for that individual. Clinical contraindications require medical judgment; no online age chart can replace a physician's examination. A court authorization and informed medical consent serve different functions, so both must be checked before transfer.
Law 5197/2025 also requires that the applicant and the carrying woman have their domicile in Greece. A former rule allowing habitual residence or temporary stay must not be repeated as current law. Domicile is a legal question that cannot safely be resolved from a hotel booking, a short visit or a clinic's marketing material. Article 46 contains a limited transitional rule for cases heard before its commencement without an irrevocable decision; only counsel reviewing the procedural file can determine whether it applies. This residence issue is essential but does not replace the medical test. The 2022 Authority decision still reproduces a reference to temporary stay, but that earlier wording cannot override the 2025 statutory change. Ask counsel to identify the current evidence of Greek domicile rather than relying on the older webpage.
Gestational carrier: biology, age and obstetric history
Greek surrogacy is gestational: Civil Code article 1458 concerns transfer of fertilized eggs that are not the carrier's own. Her own egg must not be used to create an embryo for her to carry under this procedure. An embryo may involve gametes of the intended parties or legally eligible donors, but the source, consents and traceability have to be documented through the authorized assisted-reproduction route. Genetic connection to the carrier is therefore a disqualifying design error, not a technicality that a private agreement cures.
The National Authority for Medically Assisted Reproduction's published 2022 regulatory decision sets carrier requirements of age over 25 and up to 54 and no more than two previous caesarean sections. For a carrier aged 50 years and one day through 54 years, an exceptional Authority permission is required. These figures are not the same as a guarantee of medical acceptance at that age. A clinic may assess additional risk factors and decline treatment. Verify that the 2022 decision remains unmodified at the date of treatment.
The 2022 decision says there is no numerical or time-based cap on the number of embryo-transfer attempts for a proposed carrier under the same or different court decisions. This does not mean unlimited embryos in a single transfer, unlimited stimulation for egg donors, or freedom from clinical risk controls. An unsuccessful attempt may also require the treating doctor and lawyer to revisit consent, the embryo source, the carrier's suitability and the operative reach of the court order before another cycle.
Egg and sperm donors: age, consent and genetic safety
Gamete donation is regulated separately from surrogacy permission. The Authority's public guidance describes adult donors with full legal capacity, general age ceilings below 40 for sperm donors and below 35 for egg donors, with narrowly regulated increases for specified situations. Donors undergo clinical and laboratory screening, and fresh sperm from a third-party donor is not permitted. Before using donated material, obtain a clinic's written confirmation of applicable donor-age rules, exceptions, screening results and whether the donor source is lawful. The Authority FAQ describes exceptional increases up to age 50 for sperm and 40 for egg donors in specified situations, including embryo donation or an important reason, subject to an Authority decision. That guidance must be checked against the current consolidated rules for the actual donor.
Greek law distinguishes donation without sale of gametes from regulated expense reimbursement and compensation. Donor informed consent and any required partner consent, including the donor's marital or cohabitation circumstances, need verification against the current version of Law 3305/2005. The choice between anonymous, identifiable and personally known donation must be documented, not assumed from a donor profile. In May 2026, the Authority clarified that the final paragraph of Civil Code article 1460, which says the identity of the child and the child's parents is not disclosed to third-party gamete donors, does not apply when a named/known donor wishes to donate to specific recipients already known to the donor and those recipients accept the donation.
A 2025 Authority decision on egg donation limits a donor to six ovarian-stimulation and egg-donation cycles in total and prohibits a further stimulation until four months after the last egg retrieval for donation. The June 2026 clarification states that the Authority confirmation about prior retrievals and the latest donation is valid for 45 days; where it expires without retrieval, the centre must request a new confirmation. These are donor safeguards and administrative steps, not surrogate pregnancy-count rules. Ask the clinic how registry checks are completed.
An important September 2026 Authority instruction concerns donors with identified genetic variants. It requires exclusion of donors carrying variants associated with autosomal-dominant or sex-linked conditions. For pathogenic or likely pathogenic variants associated with autosomal-recessive conditions, the Authority strongly recommends avoiding use of the donor material. If use is nevertheless considered after an individualized genetic-risk assessment, the treating clinician decides whether it may proceed, and targeted testing of the other genetic parent, detailed genetic counselling, a written counselling report in the medical file and explicit documented recipient consent are required before the cycle. Genetic screening and matching do not eliminate residual genetic risk. The instruction also requires the relevant donor-genotype data to be entered in the Authority's electronic register. The strong recommendation against use of autosomal-recessive variant material is not the same as the mandatory exclusion for dominant or sex-linked variants; any proposed use under the conditional route requires the stated safeguards.
Embryo transfer, testing and traceability
Embryo-transfer limits need to be evaluated by the treating doctor using current rules for the particular embryo source and patient. The Authority's public FAQ says that where embryos derive from donated eggs, up to two embryos may be transferred. Its FAQ also describes other limits for own-egg cycles depending on age and treatment history. Do not confuse the number of allowed embryos per transfer with the number of transfer attempts. A clinic's preference for single-embryo transfer may be more conservative for medical reasons. This is general Authority FAQ guidance, not an individual surrogacy approval. Confirm its current application to the proposed carrier and embryo source before treating the figure as a binding transfer plan.
Preimplantation genetic testing is not automatically allowed or clinically indicated for every surrogacy cycle. The Authority published updated PGT forms and directions in January 2026, referencing decision 4415/24.09.2025 (Government Gazette B 5447/13.10.2025). If testing is proposed, request the clinical indication, the precise PGT type, required Authority approval and consent forms, and the limits of what the test can detect. A donor screening panel, embryo testing and prenatal investigations answer different questions.
Before any embryo is created or transferred, identify whose sperm and eggs will be used, whether material is fresh or cryopreserved, where it originated and which licensed unit holds the traceability records. A prior donor consent does not necessarily cover every later use, and transfer between centres requires proper documentation. Record in writing who may authorize testing, storage, disposal and any change to the proposed treatment. These are diligence questions; the precise document set will depend on the laboratory and the governing consent requirements.
Decision matrix: check each gate separately
| Requirement | What to verify |
|---|---|
| Medical inability of intended mother | A specialist-supported inability to carry is the legal issue; infertility alone is not a substitute for that proof. |
| Carrier and embryos | Carrier medically fit; embryo not made from her egg; carrier age and caesarean-history rules need separate verification. |
| Donor material | Age, health and genetic screening, valid consent, donor-cycle history and traceable procurement must be checked. |
| Court and timing | Written non-remunerated agreement between the intended parties and the carrier, including the carrier's spouse if she is married; court authorization before transfer, effective only once the decision is irrevocable. |
| Clinic-specific policy | Individual obstetric risk, embryo-transfer strategy and extra laboratory testing may be stricter than the legal baseline. |
Documents, sequence and remedies
For the court and clinical files, obtain the intended mother's medical diagnosis and supporting records; the carrier's specialist health and obstetric assessment; identities and evidence relevant to Greek domicile; the proposed written agreement, including the carrier's spouse as a party if she is married; and the fertility centre's donor, embryo and screening records. Obtain the centre's current consent forms and identify any Authority permission actually needed, including for relevant age or PGT exceptions. Certified translations and document formalities should be checked with the filing lawyer, not guessed.
The sequence matters. First arrange a Greek legal eligibility review and clinical assessments; then verify donor and embryo provenance; then prepare the judicial application and obtain an irrevocable authorization; only afterwards should embryo transfer proceed. Medical clearance cannot substitute for court permission. Conversely, court permission is not an instruction to perform an unsafe procedure. If a donor fails screening, a carrier develops a contraindication or the approved arrangements materially change, stop and obtain updated clinical and legal advice rather than improvising a replacement.
A refusal needs a reason-specific response. An absence of evidence may call for additional specialist records; an adverse medical opinion requires a genuine clinical reassessment; an ineligible carrier or donor may require a new lawful candidate; and a court refusal requires Greek litigation advice on any available procedural remedy. Do not assume an internal clinic appeal reverses a statutory exclusion or that an unsigned draft judgment permits transfer. Retain dated records of the reasons given, consents and administrative decisions.
Three examples and the next decision
Consider three practical situations. If the intended mother has repeated IVF failures but no proven inability to gestate, obtain a reasoned specialist opinion before any surrogacy commitment. If the carrier is 52 and has undergone three caesareans, a special age permission alone does not cure the published caesarean restriction. If an egg donor has a potentially pathogenic recessive finding, the current genetic instruction requires a defined review and consent process, not simply a clinic's reassurance that the donor is generally healthy.
Ask any proposed clinic to cite the current Greek statutory or Authority provision behind each claimed 'legal requirement' and to identify separately what is its medical policy. Request a written eligibility matrix covering the intended mother, carrier, egg/sperm donors, embryos, consent and timing. A defensible go/no-go decision depends on both a Greek lawyer checking the live legal text and a licensed medical team reviewing the actual patient records. No website, marketing estimate or screening checklist establishes permission to begin treatment.
Sources and official guidance
- [S1] Law 5197/2025, Government Gazette A 76, article 46
- [S2] EAIYA 2022 surrogacy regulatory decision, Gazette B 5524/2022
- [S3] Law 3305/2005, reproduction law consolidated reproduction
- [S4] EAIYA, frequently asked questions
- [S5] EAIYA, official consent forms
- [S6] EAIYA 2025 egg-donor decision, Gazette B 4406/2025
- [S7] EAIYA 5 June 2026 egg-donor clarification
- [S8] EAIYA 10 September 2026 donor genetic-variant direction
- [S9] EAIYA 28 May 2026 known-donor clarification
- [S10] EAIYA 9 January 2026 PGT applications and guidance
